JCT  Vol.4 No.8 , October 2013
Nuclear Odontogenic Ameloblast-Associated Protein (ODAM) Correlates with Melanoma Sentinel Lymph Node Metastasis
Abstract: We have examined primary tumor sections from melanoma patients by immunohistochmistry (IHC) for the presence of the odontogenic ameloblast-associated protein (ODAM). Within these patient tissues we have observed a correlation of nuclear ODAM staining in the primary tumors with sentinel lymph node (SLN) metastasis. Surgically, SLN invasion in melanoma is considered an important indicator of more aggressive, invasive melanoma and to date there are limited biomarkers which strongly correlate with metastatic disease. The observation that ODAM staining in melanoma associates with SLN invasion may have important prognostic implications which could assist in the management of melanoma. Notably, ODAM expression may correlate with pathway-signaling we have previously reported to be affected by ectopic ODAM expression in cultured melanoma and breast cancer cell lines.
Cite this paper: S. Gandhi, D. Kestler, C. Bruker, J. McLaughlin, R. Heidel, S. Siddiqui, J. Foster, K. Gray, J. Bell, A. Solomon and J. Lewis, "Nuclear Odontogenic Ameloblast-Associated Protein (ODAM) Correlates with Melanoma Sentinel Lymph Node Metastasis," Journal of Cancer Therapy, Vol. 4 No. 8, 2013, pp. 1283-1289. doi: 10.4236/jct.2013.48151.

[1]   W. H. Clark Jr., D. E. Elder, D. T. Guerry, L. E. Braitman, B. J. Trock, D. Schultz, M. Synnestvedt and A. C. Halpern, “Model Predicting Survival in Stage I Melanoma Based on Tumor Progression,” Journal of the National Cancer Institute, Vol. 81, No. 24, 1989, pp. 1893-1904. jnci/81.24.1893

[2]   C. M. Balch, J. E. Gershenwald, S. J. Soong, J. F. Thompson, M. B. Atkins, D. R. Byrd, A. C. Buzaid, A. J. Cochran, D. G. Coit, S. Ding, A. M. Eggermont, K. T. Flaherty, P. A. Gimotty, J. M. Kirkwood, K. M. McMasters, M. C. Mihm Jr., D. L. Morton, M. I. Ross, A. J. Sober and V. K. Sondak, “Final Version of 2009 AJCC Melanoma Staging and Classification,” Journal of Clinical Oncology, Vol. 27, No. 36, 2009, pp. 6199-6206.

[3]   F. Amersi and D. L. Morton, “The Role of Sentinel Lymph Node Biopsy in the Management of Melanoma,” Advances in Surgery, Vol. 41, 2007, pp. 241-256. 2007.05.015

[4]   D. L. Rousseau, Jr., M. I. Ross, M. M. Johnson, V. G. Prieto, J. E. Lee, P. F. Mansfield and J. E. Gershenwald, “Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients,” Annals of Surgical Oncology, Vol. 10, No. 5, 2003, pp. 569-574.

[5]   D. L. Morton, J. F. Thompson, R. Essner, R. Elashoff, S. L. Stern, O. E. Nieweg, D. F. Roses, C. P. Karakousis, N. Mozzillo, D. Reintgen, H. J. Wang, E. C. Glass and A. J. Cochran, “Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma: A Multicenter Trial. Multicenter Selective Lymphadenectomy Trial Group,” Annals of Surgery, Vol. 230, No. 4, 1999, pp. 453-463, Discussion 463-455.

[6]   B. E. Gould Rothberg, M. B. Bracken and D. L. Rimm, “Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-Analysis,” Journal of the National Cancer Institute, Vol. 101, No. 7, 2009, pp. 452-474.

[7]   I. Yajima, M. Y. Kumasaka, N. D. Thang, Y. Goto, K. Takeda, O. Yamanoshita, M. Iida, N. Ohgami, H. Tamura, Y. Kawamoto and M. Kato, “RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy,” Dermatology Research and Practice, Vol. 2012, 2012, Article ID: 354191.

[8]   A. Solomon, C. L. Murphy, K. Weaver, D. T. Weiss, R. Hrncic, M. Eulitz, R. L. Donnell, K. Sletten, G. Westermark and P. Westermark, “Calcifying Epithelial Odontogenic (Pindborg) Tumor-Associated Amyloid Consists of a Novel Human Protein,” Journal of Laboratory and Clinical Medicine, Vol. 142, No. 5, 2003, pp. 348-355.

[9]   D. P. Kestler, J. S. Foster, S. D. Macy, C. L. Murphy, D. T. Weiss and A. Solomon, “Expression of Odontogenic Ameloblast-Associated Protein (ODAM) in Dental and Other Epithelial Neoplasms,” Molecular Medicine, Vol. 14, No. 5-6, 2008, pp. 318-326.

[10]   S. Siddiqui, C. T. Bruker, D. P. Kestler, J. S. Foster, K. D. Gray, A. Solomon and J. L. Bell, “Odontogenic Ameloblast Associated Protein as a Novel Biomarker for Human Breast Cancer,” The American Surgeon, Vol. 75, No. 9, 2009, pp. 769-775.

[11]   J. C. Park, J. T. Park, H. H. Son, H. J. Kim, M. J. Jeong, C. S. Lee, R. Dey and M. I. Cho, “The Amyloid Protein APin is Highly Expressed during Enamel Mineralization and Maturation in Rat Incisors,” European Journal of Oral Sciences, Vol. 115, No. 2, 2007, pp. 153-160. /j.1600-0722.2007.00435.x

[12]   P. Moffatt, C. E. Smith, R. St-Arnaud and A. Nanci, “Characterization of Apin, a Secreted Protein Highly Expressed in Tooth-Associated Epithelia,” Journal of Cellular Biochemistry, Vol. 103, No. 3, 2008, pp. 941-956.

[13]   H. K. Lee, D. S. Lee, H. M. Ryoo, J. T. Park, S. J. Park, H. S. Bae, M. I. Cho and J. C. Park, “The Odontogenic Ameloblast-Associated Protein (ODAM) Cooperates with RUNX2 and Modulates Enamel Mineralization via Regulation of MMP-20,” Journal of Cellular Biochemistry, Vol. 111, No. 3, 2010, pp. 755-767.

[14]   C. Nishio, R. Wazen, S. Kuroda, P. Moffatt and A. Nanci, “Expression Pattern of Odontogenic Ameloblast-Associated and Amelotin during Formation and Regeneration of the Junctional Epithelium,” European Cells and Materials, Vol. 20, 2010, pp. 393-402.

[15]   M. Fukunaga-Kalabis, A. Santiago-Walker and M. Herlyn, “Matricellular Proteins Produced by Melanocytes and Melanomas: In Search for Functions,” Cancer Microenvironment, Vol. 1, No. 1, 2008, pp. 93-102.

[16]   A. J. Berger, H. M. Kluger, N. Li, E. Kielhorn, R. Halaban, Z. Ronai and D. L. Rimm, “Subcellular Localization of Activating Transcription Factor 2 in Melanoma Specimens Predicts Patient Survival,” Cancer Research, Vol. 63, No. 23, 2003, pp. 8103-8107.

[17]   R. G. Bedolla, Y. Wang, A. Asuncion, K. Chamie, S. Siddiqui, M. M. Mudryj, T. J. Prihoda, J. Siddiqui, A. M. Chinnaiyan, R. Mehra, R. W. de Vere White and P. M. Ghosh, “Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases,” Clinical Cancer Research, Vol. 15, No. 3, 2009, pp. 788-796.

[18]   J. J. Derry, G. S. Prins, V. Ray and A. L. Tyner, “Altered Localization and Activity of the Intracellular Tyrosine Kinase BRK/Sik in Prostate Tumor Cells,” Oncogene, Vol. 22, No. 27, 2003, pp. 4212-4220.

[19]   S. P. Tenbaum, P. Ordonez-Moran, I. Puig, I. Chicote, O. Arques, S. Landolfi, Y. Fernandez, J. R. Herance, J. D. Gispert, L. Mendizabal, S. Aguilar, S. Ramon y Cajal, S. Schwartz, Jr., A. Vivancos, E. Espin, S. Rojas, J. Baselga, J. Tabernero, A. Munoz and H. G. Palmer, “Beta-Catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer,” Nature Medicine, Vol. 18, No. 6, 2012, pp. 892-901.

[20]   N. K. Haass and K. S. Smalley, “Melanoma Biomarkers: Current Status and Utility in Diagnosis, Prognosis, and Response to Therapy,” Molecular Diagnosis and Therapy, Vol. 13, No. 5, 2009, pp. 283-296.

[21]   A. R. Larson, E. Konat and R. M. Alani, “Melanoma Biomarkers: Current Status and Vision for the Future,” Nature Clinical Practice Oncology, Vol. 6, No. 2, 2009, pp. 105-117. 10.1038/ncponc1296

[22]   C. W. Joyce, I. G. Murphy, M. Rafferty, D. Ryan, E. W. McDermott and W. M. Gallagher, “Tumor Profiling Using Protein Biomarker Panels in Malignant Melanoma: Application of Tissue Microarrays and Beyond,” Expert Review of Proteomics, Vol. 9, No. 4, 2012, pp. 415-423. 10.1586/epr.12.5

[23]   T. S. Wang, T. M. Johnson, P. N. Cascade, B. G. Redman, V. K. Sondak and J. L. Schwartz, “Evaluation of Staging Chest Radiographs and Serum Lactate Dehydrogenase for Localized Melanoma,” Journal of the American Academy of Dermatology, Vol. 51, No. 3, 2004, pp. 399-405. 10.1016/j.jaad.2004.02.017

[24]   U. Bottoni, P. Izzo, A. Richetta, T. J. Mannooranparampil, V. Devirgiliis, M. Del Giudice, M. G. Reale, L. Frati and S. Calvieri, “S100 Serum Level: A Tumour Marker for Metastatic Melanoma,” Melanoma Research, Vol. 13, No. 4, 2003, pp. 427-429.

[25]   S. Pasquali, A. P. van der Ploeg, S. Mocellin, J. R. Stretch, J. F. Thompson and R. A. Scolyer, “Lymphatic Biomarkers in Primary Melanomas as Predictors of Regional Lymph Node Metastasis and Patient Outcomes,” Pigment Cell and Melanoma Research, Vol. 26, No. 3, 2013, pp. 326-337.

[26]   P. P. Aung, M. Sarlomo-Rikala, J. Lasota, J. P. Lai, Z. F. Wang and M. Miettinen, “KBA62 and PNL2: 2 New Melanoma Markers-Immunohistochemical Analysis of 1563 Tumors Including Metastatic, Desmoplastic, and Mucosal Melanomas and Their Mimics,” American Journal of Surgical Pathology, Vol. 36, No. 2, 2012, pp. 265-272.

[27]   D. P. Kestler, J. S. Foster, C. T. Bruker, J. W. Prenshaw, S. J. Kennel, J. S. Wall, D. T. Weiss and A. Solomon, “ODAM Expression Inhibits Human Breast Cancer Tumorigenesis,” Breast Cancer: Basic and Clinical Research (Auckl), Vol. 5, 2011, pp. 73-85.

[28]   J. S. Foster, L. M. Fish, J. E. Phipps, C. T. Bruker, J. M. Lewis, J. L. Bell, A. Solomon and D. P. Kestler, “Odontogenic Ameloblast-Associated Protein (ODAM) Inhibits Growth and Migration of Human Melanoma Cells and Elicits PTEN Elevation and INACTIVATION of PI3K/ AKT Signaling,” BMC Cancer, Vol. 13, 2013, p. 227.

[29]   J. A. Curtin, J. Fridlyand, T. Kageshita, H. N. Patel, K. J. Busam, H. Kutzner, K. H. Cho, S. Aiba, E. B. Brocker, P. E. LeBoit, D. Pinkel and B. C. Bastian, “Distinct Sets of Genetic Alterations in Melanoma,” New England Journal of Medicine, Vol. 353, No. 20, 2005, pp. 2135-2147. NEJMoa050092

[30]   H. Tsao, V. Goel, H. Wu, G. Yang and F. G. Haluska, “Genetic Interaction between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma,” Journal of Investigative Dermatology, Vol. 122, No. 2, 2004, pp. 337-341.

[31]   L. P. Cantini, F. Meier, V. K. Sondak and K. S. Smalley, “The Future of Targeted Therapy Approaches in Melanoma,” Expert Opinion on Drug Discovery, Vol. 4, No. 4, 2009, pp. 445-456. 10.1517/17460440902828298

[32]   W. H. Chappell, L. S. Steelman, J. M. Long, R. C. Kempf, S. L. Abrams, R. A. Franklin, J. Basecke, F. Stivala, M. Donia, P. Fagone, G. Malaponte, M. C. Mazzarino, F. Nicoletti, M. Libra, D. Maksimovic-Ivanic, S. Mijatovic, G. Montalto, M. Cervello, P. Laidler, M. Milella, A. Tafuri, A. Bonati, C. Evangelisti, L. Cocco, A. M. Martelli and J. A. McCubrey, “Ras/Raf/MEK/ERK and PI3K/ PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health,” Oncotarget, Vol. 2, No. 3, 2011, pp. 135-164.

[33]   J. B. Korman and D. E. Fisher, “Developing Melanoma Therapeutics: Overview and Update,” Wiley Interdisciplinary Reviews: Systems Biology and Medicine, Vol. 5, No. 3, 2013, pp. 257-271. 1210

[34]   T. Shimizu, A. W. Tolcher, K. P. Papadopoulos, M. Beeram, D. W. Rasco, L. S. Smith, S. Gunn, L. Smetzer, T. A. Mays, B. Kaiser, M. J. Wick, C. Alvarez, A. Cavazos, G. L. Mangold and A. Patnaik, “The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/ mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer,” Clinical Cancer Research, Vol. 18, No. 8, 2012, pp. 2316-2325.

[35]   S. J. Vidwans, K. T. Flaherty, D. E. Fisher, J. M. Tenenbaum, M. D. Travers and J. Shrager, “A Melanoma Molecular Disease Model,” PLoS One, Vol. 6, No. 3, 2011, Article ID: e18257. journal.pone.0018257